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background: Few studies investigated serum uric acid levels in patients with acute myocardial infarction (AMI) at admission. The study was to 
assess the prognostic value of serum uric acid levels in patients with AMI.
methods: Totally 3,239 consecutive patients with AMI were retrospectively studied from January 2005 to December 2011 [ST elevation myocardial 
infarction (STEMI): n= 1,512, Non ST elevation myocardial infarction: n=1,727]. STEMI patients (65.4 ±12.3 years, 73.2% male) who underwent 
primary PCI and divided them into 2 groups according to serum uric acid level (Non-hyperurecemia group: n=1,226, Hyperurecemia group: n=286) 
and Non-STEMI (64.7 ±12.9 years, 82.3% male) who underwent primary PCI and divided them into 2 groups according to serum uric acid level 
(Non-hyperurecemia group: n=1,422, Hyperurecemia group: n=305) patients followed them up for 12 months. The primary outcomes were 12-month 
major adverse cardiac events (MACEs), a composite of cardiac death, fatal and non-fatal MI, and target vessel revascularization, and coronary artery 
bypass grafting.
results: First, in STEMI patients, the incidence of 12-month MACEs was higher in Hyperuricemia group than in non-Hypperuricemia group (20.6 vs. 
7.0%, p< 0.01) Kaplan Meier analysis showed significant difference between two groups (p<0.01 by log rank). Independent predictors of 12-month 
MACEs were decreased renal function (OR 2.104, 95% CI 1.479-2.993, p<0.01), low admission systolic blood pressure (Systolic blood pressure < 
90mmHg, OR 11.36, 95% CI 2.812-45.945, p=0.001).  In non-STEMI patients, the incidence of 12-month MACEs was higher in Hyperuricemia group 
than in non-Hypperuricemia group (29.5 vs. 9.8%, p< 0.01) Kaplan Meier analysis showed significant difference between two groups (p<0.01 by log 
rank). Independent predictors of 12-month MACEs were decreased renal function (OR 1.987, 95% CI 1.468-2.689, p<0.01).
Conclusions: Hyperuricemia had critical impact on poor outcome in AMI patients. Checking admission serum uric acid level might be useful for 
predict prognosis in AMI patients.
